{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:34Z","timestamp":1761986554203,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_160115\/1","32473B_185008"],"award-info":[{"award-number":["32003B_160115\/1","32473B_185008"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaip.2021.07.031","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T11:29:53Z","timestamp":1627730993000},"page":"3276-3281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Emerging Therapies for Eosinophilic Gastrointestinal Diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Kathryn","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Safroneeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Schoepfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.07.031_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.29262\/ram.v65i2.354","article-title":"Epidemiological, clinical and diagnostic characterization of children with eosinophilic gastroenteropathy. A retrospective study of three high complexity health institutions [in Spanish]","volume":"65","author":"Holgu\u00edn","year":"2018","journal-title":"Rev Alerg Mex"},{"key":"10.1016\/j.jaip.2021.07.031_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","article-title":"Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis","volume":"121","author":"Egan","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jaip.2018.06.012","article-title":"Eosinophilic esophagitis and the eosinophilic gastrointestinal diseases: approach to diagnosis and management","volume":"6","author":"Steinbach","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.07.031_bib4","first-page":"265","article-title":"Elements involved in promoting eosinophilic gastrointestinal disorders","volume":"6","author":"Shukla","year":"2015","journal-title":"J\u00a0Genet Syndr Gene Ther"},{"key":"10.1016\/j.jaip.2021.07.031_bib5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2017.05.050","article-title":"Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017","volume":"15","author":"Mansoor","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2021.07.031_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12016-015-8489-4","article-title":"Eosinophilic gastroenteritis and colitis: a comprehensive review","volume":"50","author":"Uppal","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/all.14148","article-title":"Eosinophilic esophagitis and allergic comorbidities in a US-population-based study","volume":"75","author":"Cianferoni","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.07.031_bib8","doi-asserted-by":"crossref","first-page":"G879","DOI":"10.1152\/ajpgi.00174.2018","article-title":"Eosinophilic esophagitis\u2014pathophysiology and its clinical implications","volume":"315","author":"Inage","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jaip.2021.07.031_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MPG.0000000000000865","article-title":"Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database","volume":"62","author":"Jensen","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaip.2021.07.031_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/1744666X.2019.1544893","article-title":"Pathophysiology of eosinophilic esophagitis: recent advances and their clinical implications","volume":"15","author":"Ruffner","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.yexmp.2015.08.012","article-title":"The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice","volume":"99","author":"Chien","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jaip.2021.07.031_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bpg.2015.09.003","article-title":"The genetic basis of eosinophilic esophagitis","volume":"29","author":"Sleiman","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jaip.2021.07.031_bib13","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1038\/ncomms6593","article-title":"GWAS identifies four novel eosinophilic esophagitis loci","volume":"5","author":"Sleiman","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2021.07.031_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2019.11.007","article-title":"Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: multi-site study","volume":"145","author":"Shoda","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.anai.2020.03.020","article-title":"AGA Institute and the Joint Task Force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"124","author":"Hirano","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","article-title":"Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"gastroenterology"},{"key":"10.1016\/j.jaip.2021.07.031_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2021.07.031_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.gastro.2003.07.007","article-title":"Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism","volume":"125","author":"Mishra","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2021.07.031_bib19","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaip.2021.07.031_bib21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2021.07.031_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years","volume":"66","author":"Markowitz","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaip.2021.07.031_bib24","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/MPG.0000000000002087","article-title":"Efficacy of reslizumab for eosinophilic esophagitis","volume":"67","author":"Fuchs","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaip.2021.07.031_bib25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(R\u03b1)\u2013targeted therapy: an overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.07.031_bib26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.07.031_bib27","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2007.10.024","article-title":"IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids","volume":"120","author":"Blanchard","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib28","doi-asserted-by":"crossref","first-page":"e86355","DOI":"10.1172\/jci.insight.86355","article-title":"Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment","volume":"1","author":"Davis","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2021.07.031_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.07.031_bib30","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, a novel anti-interleukin-13 antibody, blocks il-13 binding to il-13 \u03b11 and \u03b12 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study","volume":"34","author":"Tripp","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2021.07.031_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2021.07.031_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","article-title":"Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis","volume":"19","author":"Dellon","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2021.07.031_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2021.07.031_bib34","doi-asserted-by":"crossref","first-page":"e126219","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2021.07.031_bib35","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.07.031_bib36","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.alit.2018.03.006","article-title":"Expression of Siglec-8 is regulated by interleukin-5, and serum levels of soluble Siglec-8 may predict responsiveness of severe eosinophilic asthma to mepolizumab","volume":"67S","author":"Arakawa","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2021.07.031_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41395-018-0145-1","article-title":"The anti-\u03b14\u03b27 Integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates eosinophilic esophagitis: a novel clinical observation","volume":"113","author":"Nhu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaip.2021.07.031_bib38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.06.022","article-title":"The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn's disease","volume":"16","author":"Taft","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2021.07.031_bib39","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.cgh.2018.03.024","article-title":"Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2021.07.031_bib40","doi-asserted-by":"crossref","first-page":"e232558","DOI":"10.1136\/bcr-2019-232558","article-title":"Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib","volume":"12","author":"Mendoza Alvarez","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2021.07.031_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/resp.13711","article-title":"Combined blockade of IL-25, IL-33 and TSLP mediates amplified inhibition of airway inflammation and remodelling in a murine model of asthma","volume":"25","author":"An","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2021.07.031_bib42","doi-asserted-by":"crossref","first-page":"e0150968","DOI":"10.1371\/journal.pone.0150968","article-title":"Preferential secretion of thymic stromal lymphopoietin (TSLP) by terminally differentiated esophageal epithelial cells: relevance to eosinophilic esophagitis (EoE)","volume":"11","author":"Chandramouleeswaran","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.07.031_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.actatropica.2009.10.017","article-title":"Anti-CCR3 monoclonal antibody inhibits eosinophil infiltration in Angiostrongylus cantonensis\u2013infected ICR mice","volume":"113","author":"Chuang","year":"2010","journal-title":"Acta Trop"},{"key":"10.1016\/j.jaip.2021.07.031_bib44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","volume":"9","author":"Vicari","year":"2017","journal-title":"MAbs"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821008357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821008357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:41Z","timestamp":1761974921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821008357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2213219821008357"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.07.031","relation":{},"ISSN":["2213-2198"],"issn-type":[{"type":"print","value":"2213-2198"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapies for Eosinophilic Gastrointestinal Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}